Overview

• AbbVie announced on June 30 that it will acquire Capstan for up to $2.1 billion in cash, pending customary Hart-Scott-Rodino Act antitrust clearance.
• The agreement covers CPTX2309, Capstan’s Phase 1 anti-CD19 CAR-T therapy aimed at B cell–mediated autoimmune diseases.
• AbbVie will also gain Capstan’s targeted lipid nanoparticle (tLNP) platform for in vivo RNA delivery to engineer specific cell types.
• Following the deal announcement, AbbVie shares rose about 0.5% to $183.20 in early trading, reflecting positive investor response.
• The acquisition positions AbbVie to advance its in vivo cell-engineering programs and supports its strategy to address autoimmune diseases at their root.